Commonwealth Diagnostics relaunches GI diagnostic testing business in US — 3 insights

Eric Oliver - Print  |

Commonwealth Diagnostics relaunched its U.S.-based gastroenterology diagnostic testing business.

Here's what you should know:

1. The relaunch includes CDI's hydrogen and methane breath testing portfolio, and was made possible in part because of the "positive momentum and recognition" the company received at Digestive Disease Week, May 6 to May 9 in Chicago.

2. CDI is in the midst of expanding its offerings to U.S.-based and global patients. CDI recently:

Adopted North American Consensus Standards on hydrogen and methane breath testing
Received ISO 13485 certification and CE Marking for the aforementioned breath testing kits
Entered into a series of joint ventures and commercial partnerships to make its products available in the U.S., Latin America and United Kingdom
Sponsored The Rome Foundation to help guide physicians and researchers as they care for patients with functional GI disorders

3. CDI President and CEO Craig Strasnick said in a release, "This is an exciting time for CDI as we are able to return to our heritage and deliver our industry-leading model of service and simplicity to our healthcare providers throughout the U.S. These new developments will allow CDI to focus on our current portfolio of diagnostic tests in the U.S., while also introducing new technologies that will help to facilitate the diagnosis of gastrointestinal disorders in the future as we advance our growing R&D program across a broad spectrum of GI health areas."

More articles on gastroenterology:
GI center to know: Chicago Endoscopy Center
AzurRx BioPharma's clinical trial hits midway point & more — 3 GI company key notes
Dr. Nitin Kumar speaking to community — 3 key notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.